ReviewArchives of microbiology2025
Research progress on the synergistic effect and its mechanisms of antidepressants and antibiotics against resistant pathogens.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Preventive Activity of Paroxetine Against the Formation of Mixed Biofilms of Candida albicans and Staphylococcus aureus on Peripheral Venous Catheters.Current microbiology · 2026Article
- The synergistic antibacterial and anti-biofilm effects of fluoxetine and quercetin against carbapenemase producing Stenotrophomonas maltophilia clinical isolates.Molecular biology reports · 2026Article
- The interplay between inflammation and oxidative stress in depression: pathogenic mechanisms and treatment approaches.Molecular biology reports · 2025Review
- Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance.International journal of molecular sciences · 2025Review
- Antibacterial Evaluation of Tricyclic Antidepressants AgainstPathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antimicrobial resistance (AMR) poses a critical global health challenge, driving the urgent need for innovative therapeutic strategies. Antidepressants, traditionally used for major depressive disorders (MDD), have recently attracted attention in non-antibiotic research due to their diverse pharmacological properties, including antimicrobial, antifungal, antiviral, anticancer, antiparasitic, and anti-inflammatory activities. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) demonstrated synergistic antimicrobial effects with reduced minimum inhibitory concentrations (MIC) when used in combination with conventional antibiotics, enhancing efficacy against drug-resistant pathogens. Mechanisms underlying this synergy include inhibition of bacterial efflux pumps and disruption of membrane integrity. Despite these promising findings, in vivo studies evaluating antidepressant-antibiotic synergy remain scarce, underscoring the need for further mechanistic and translational research to overcome challenges in clinical application. Overall, antidepressants show significant potential as adjuvants to antibiotics against resistant bacteria, making them promising candidates for combination therapy.
Indexed as
Identifiers
40439891What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.